Priority 4 from the Mitochondrial Disease PSP
| UNCERTAINTY: What biomarkers (biological markers that can be measured e.g. in blood samples) could be used to diagnose mitochondrial disease and to track its progress? (JLA PSP Priority 4) | |
|---|---|
| Overall ranking | 4 |
| JLA question ID | 0095/4 |
| Explanatory note | Not available |
| Evidence |
https://pubmed.ncbi.nlm.nih.gov/27794108%20https://pmc.ncbi.nlm.nih.gov/articles/PMC5841218/%20%20https://pubmed.ncbi.nlm.nih.gov/29735722/ |
| Health Research Classification System category | Metabolic and Endocrine |
| Extra information provided by this PSP | |
|---|---|
| Original uncertainty examples | A way to monitor progression. ~ Maybe research could Show what the best blood tests would be needed to spot progression or health changes. ~ Progression : identification of bio markers of progressive disease ~ Are there biomarkers (e.g. on retinal imaging) for progression of mitochondrial retinopathy? ~ Pathognomic features or biomerkers for early detection of the disease. ~ Research on diagnostic markers ~ Biomarkers. ~ studies designed to identify prognostic biomarkers and trial endpoints |
| Submitted by | 6 x Healthcare Professionals, 2 x Carers |
| PSP information | |
|---|---|
| PSP unique ID | 0095 |
| PSP name | Mitochondrial Disease |
| Total number of uncertainties identified by this PSP. | 42 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 19 January 2020 |